PEGylated Chitosan-Based Polymer Micelle As an Intracellular Delivery Carrier for Anti-Tumor Targeting Therapy.

Fu-Qiang Hu,Pan Meng,You-Qin Dai,Yong-Zhong Du,Jian You,Xiao-Hong Wei,Hong Yuan
DOI: https://doi.org/10.1016/j.ejpb.2008.06.015
IF: 5.589
2008-01-01
European Journal of Pharmaceutics and Biopharmaceutics
Abstract:Stearic acid-grafted chitosan oligosaccharide (CSO-SA) micelles presented a potential candidate for intracellular drug delivery carrier due to its special spatial structure. In this article, CSO-SA was further modified by polyethylene glycol (PEG). The physicochemical properties of PEGylated CSO-SA (PEG-CSO-SA) micelles were characterized. After PEGylation, the critical micelle concentration (CMC) of PEG-CSO-SA had no significant change; the micelle size increased; and the zeta potential decreased. The cellular uptake of CSO-SA micelles before and after PEGylation in macrophage RAW264.7, immortalized rat liver cells BRL-3A and human liver tumor cells HepG2 was studied. About 58.4±0.63% of CSO-SA micelles were uptaked by RAW264.7 in 24h, however, only 17.7±0.94% of PEG-CSO-SA micelles were internalized into RAW264.7 after the CSO-SA was modified with PEG in five molar times. Meanwhile, there were no changes in the uptake after PEGylation of CSO-SA in BRL-3A and HepG2. Using mitomycin C as a model drug, the in vitro anti-tumor activities of the drug loaded in the micelles were investigated. The 50% cellular growth inhibition (IC50) of the drug decreased from 1.97±0.2 to 0.13±0.02μg/mL after mitomycin C was loaded into CSO-SA micelles, and the IC50 value of the drug had no obvious change when the CSO-SA was modified by PEG.
What problem does this paper attempt to address?